Axsome Therapeutics (AXSM) Given Coverage Optimism Rating of 0.16

Media headlines about Axsome Therapeutics (NASDAQ:AXSM) have been trending somewhat positive recently, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by reviewing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Axsome Therapeutics earned a news sentiment score of 0.16 on Accern’s scale. Accern also gave media stories about the company an impact score of 45.0674291644669 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.

Here are some of the news articles that may have impacted Accern Sentiment Analysis’s rankings:

Several research firms have recently issued reports on AXSM. Zacks Investment Research raised Axsome Therapeutics from a “hold” rating to a “buy” rating and set a $5.25 target price on the stock in a report on Tuesday. Aegis reissued a “buy” rating and set a $20.00 target price on shares of Axsome Therapeutics in a report on Tuesday, June 20th. ValuEngine raised Axsome Therapeutics from a “strong sell” rating to a “sell” rating in a report on Wednesday, June 21st. Finally, BTIG Research began coverage on Axsome Therapeutics in a report on Friday, May 19th. They set a “buy” rating and a $14.00 target price on the stock. One analyst has rated the stock with a sell rating and six have given a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $17.21.

Axsome Therapeutics (NASDAQ:AXSM) traded up 0.64% during mid-day trading on Wednesday, hitting $4.73. The stock had a trading volume of 22,932 shares. The company’s 50 day moving average is $5.31 and its 200-day moving average is $4.67. The stock’s market capitalization is $111.68 million. Axsome Therapeutics has a 52 week low of $3.53 and a 52 week high of $9.11.

Axsome Therapeutics (NASDAQ:AXSM) last released its quarterly earnings data on Wednesday, August 9th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.31) by $0.01. On average, analysts expect that Axsome Therapeutics will post ($1.38) EPS for the current fiscal year.

ILLEGAL ACTIVITY WARNING: “Axsome Therapeutics (AXSM) Given Coverage Optimism Rating of 0.16” was first published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://stocknewstimes.com/2017/09/13/axsome-therapeutics-axsm-given-coverage-optimism-rating-of-0-16.html.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders, including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate, AXS-02 (disodium zoledronate tetrahydrate), is an oral, targeted, non opioid therapeutic for chronic pain.

Insider Buying and Selling by Quarter for Axsome Therapeutics (NASDAQ:AXSM)

Receive News & Ratings for Axsome Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Axsome Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply